Slingshot members are tracking this event:

Gilead (GILD) Presents 48-Week Phase 2 Data Evaluating HIV-1 Infection Regimen Bictegravir (B/F/TAF) in Combination with Dolutegravir at the Annual Conference on Retroviruses and Opportunistic Infections (CROI)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 13, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords 48-week Data, Phase 2, Hiv-1 Infection Regimen, Bictegravir, Dolutegravir, Croi